Vertex制药公司看到投资增长, 尽管Q1收入亏损, 评级为“移动买家”。 Vertex Pharmaceuticals sees investment growth despite Q1 earnings miss, rated "Moderate Buy."

Vertex制药公司今年实现了机构投资增长,顾问优先的LLC公司和Wedbush证券公司等公司增加了股份。 Vertex Pharmaceuticals saw institutional investment growth this year, with firms like Advisors Preferred LLC and Wedbush Securities Inc. increasing their shares. 尽管Q1收益失败, 股票被评为"中等买入" Despite a Q1 earnings miss, the stock is rated "Moderate Buy" with a $511.71 target price. 这家生物技术公司专业从事囊性纤维化治疗, 市值为120.73亿美元. The biotech company specializes in cystic fibrosis treatments and has a market cap of $120.73 billion.